

ABSTRACT

A method for delivering a nucleic acid of interest to a host cell (“gene therapy”) using a gene delivery vehicle based on adenoviral material. The gene delivery vehicle delivers the nucleic acid of interest to the host cell by associating with a binding site and/or a receptor present on adenovirus serotype 5 Coxsacki adenovirus receptor (“CAR”) -negative cells. The binding site and/or receptor is a binding site for adenovirus subgroup D and/or adenovirus subgroup F. Associated methods and pharmaceutical compositions are also disclosed.